U.S. Markets closed

Chelsea Therapeutics target raised to $18 from $6 at Roth Capital

Roth Capital raised its target on Chelsea Therapeutics as the firm has increased confidence in the company's Northera drug after data on the treatment was submitted at a recent conference. The firm expects the drug to be approved as early as 1Q12, and it maintains a Buy rating on the stock.